Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov;60(11):2200-2209.
doi: 10.1007/s00125-017-4402-4. Epub 2017 Aug 23.

Screening for type 2 diabetes: do screen-detected cases fare better?

Affiliations

Screening for type 2 diabetes: do screen-detected cases fare better?

Adina L Feldman et al. Diabetologia. 2017 Nov.

Abstract

Aims/hypothesis: We aimed to investigate whether diabetes cases detected through screening have better health outcomes than clinically detected cases in a population-based cohort of adults who were eligible to be screened for diabetes at 10 year intervals.

Methods: The Västerbotten Intervention Programme is a community- and individual-based public health programme in Västerbotten County, Sweden. Residents are invited to clinical examinations that include screening for diabetes by OGTTs at age 30, 40, 50 and 60 years (individuals eligible for screening, n = 142,037). Between 1992 and 2013, we identified 1024 screen-detected cases and 8642 clinically detected cases of diabetes using registry data. Clinically detected individuals were either prior screening participants (n = 4506) or people who did not participate in screening (non-participants, n = 4136). Study individuals with diabetes were followed from date of detection until end of follow-up, emigration, death or incident cardiovascular disease (CVD), renal disease or retinopathy event, and compared using Cox proportional hazard regression adjusted for calendar time, age at detection, year of detection, sex and socioeconomic status.

Results: The average age at diabetes diagnosis was 4.6 years lower for screen-detected individuals compared with clinically detected individuals. Overall, those who were clinically detected had worse health outcomes than those who were screen-detected (HR for all-cause mortality 2.07 [95% CI 1.63, 2.62]). Compared with screen-detected study individuals, all-cause mortality was higher for clinically detected individuals who were screening non-participants (HR 2.31 [95% CI 1.82, 2.94]) than for those clinically detected who were prior screening participants (HR 1.70 [95% CI 1.32, 2.18]). Estimates followed a similar pattern for CVD, renal disease and retinopathy.

Conclusions/interpretation: Individuals with screen-detected diabetes were diagnosed earlier and appeared to fare better than those who were clinically detected with regard to all-cause mortality, CVD, renal disease and retinopathy. How much of these associations can be explained by earlier treatment because of screening rather than healthy user bias, lead time bias and length time bias warrants further investigation.

Keywords: Diabetes mellitus; Early diagnosis; Epidemiology; Mass screening; Public health.

PubMed Disclaimer

Conflict of interest statement

Data availability

Data from the Västerbotten Intervention Study may be obtained from the corresponding author on reasonable request; all linked datasets may be obtained separately from the various register holders, as listed in the Methods section.

Duality of interest

SJG declares receipt of an honorarium and reimbursement of travel expenses from Eli Lilly associated with membership of an independent data-monitoring committee for a randomised trial of a medication to lower glucose, and receipt of honoraria for speaking at postgraduate educational meetings from Janssen and Astra Zeneca. All other authors declare no duality of interest associated with this manuscript.

Contribution statement

ALF designed the analysis plan, performed the data analyses, interpreted the results and drafted and critically revised the manuscript. OR conceived the study question, obtained the data, contributed to the analysis plan, interpreted the results and critically revised the manuscript. SJG contributed to the analysis plan, interpreted the results and critically revised the manuscript. LW and MN coordinated the data collection in the Västerbotten Intervention Study, contributed to the analysis plan and critically revised the manuscript. EF and PW contributed to the analysis plan and critically revised the manuscript. All authors have approved the final version of the manuscript. OR is the guarantor of this work.

Figures

Fig. 1
Fig. 1
Flow chart describing the study population. The prevalent diabetes-free study population (N = 140,276) was eligible for screening; 46,209 individuals did not participate in screening and 94,067 did. Among the screening participants, 16,214 had non-diabetic hyperglycaemia (n = 1898 were later detected clinically) and 3483 screened positive for diabetes. Of those who screened positive, the diagnosis was confirmed within 1 year in 1024 individuals, and remained unconfirmed in 1403 (n = 280 were found to have diabetes other than type 2). A total of 776 individuals were clinically detected after having screened positive for diabetes more than 1 year previously, 1716 were clinically detected after having normoglycaemia in screening, and 116 were clinically detected after participating in a health examination without completing an OGTT. In total, among all screening participants, n = 4506 cases of diabetes were clinically detected, whilst in screening non-participants, 4136 cases of diabetes were clinically detected. Dashed lines indicate that downstream boxes do not include all individuals in upstream box, solid lines indicate that all individuals in upstream box are accounted for in downstream boxes

References

    1. International Diabetes Federation (2015) IDF diabetes atlas, 7th edn. Available from www.diabetesatlas.org/. Accessed 31 July 2017
    1. Simmons RK, Echouffo-Tcheugui JB, et al. Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Lancet. 2012;380:1741–1748. doi: 10.1016/S0140-6736(12)61422-6. - DOI - PMC - PubMed
    1. Simmons RK, Griffin SJ, Witte DR, Borch-Johnsen K, Lauritzen T, Sandbæk A (2017) Effect of population screening for type 2 diabetes and cardiovascular risk factors on mortality rate and cardiovascular events: a controlled trial among 1,912,392 Danish adults. Diabetologia DOI 10.1007/s00125-017-4323-2 - PMC - PubMed
    1. Simmons RK, Rahman M, Jakes RW, et al. Effect of population screening for type 2 diabetes on mortality: long-term follow-up of the Ely cohort. Diabetologia. 2011;54:312–319. doi: 10.1007/s00125-010-1949-8. - DOI - PubMed
    1. Rahman M, Simmons RK, Hennings SH, Wareham NJ, Griffin SJ. How much does screening bring forward the diagnosis of type 2 diabetes and reduce complications? Twelve year follow-up of the Ely cohort. Diabetologia. 2012;55:1651–1659. doi: 10.1007/s00125-011-2441-9. - DOI - PubMed